---
id: herpes-zoster-disseminated
condition: Disseminated Herpes Zoster
aliases: [disseminated shingles, disseminated VZV, generalized zoster]
icd10: [B02.7, B02.8]
esi: 2
time_to_harm: "< 48 hours (VZV pneumonitis, encephalitis); < 72 hours (DIC, multi-organ failure)"
category: dermatologic
track: tier1
sources:
  - type: guideline
    ref: "NIH Guidelines for Prevention and Treatment of Opportunistic Infections: Varicella-Zoster Virus, 2024"
  - type: guideline
    ref: "IDSA Clinical Practice Guideline for the Management of VZV Infections"
  - type: review
    ref: "Disseminated Zoster in an Immunocompromised Patient. Brown Emergency Medicine, 2024"
last_updated: "2026-03-01"
compiled_by: agent
risk_tier: A
validation:
  automated_consistency_check: null
  dose_range_validator: null
  unit_normalization_check: null
  cross_file_consistency_check: null
  citation_presence_check: null
  duplicate_content_check: null
  outlier_detection_flag: clear
  schema_version: "2.0"
  provenance_links: []
---
# Disseminated Herpes Zoster

## Recognition

**Definition:**
- > 20 vesicular lesions outside the primary and adjacent dermatomes
- OR generalized varicelliform eruption in a patient with prior VZV history
- Effectively represents viremic spread of reactivated VZV

**Skin presentation:**
- Initial dermatomal vesicular rash (grouped vesicles on erythematous base)
- Followed by widespread vesicles beyond dermatome
- Lesions at various stages (vesicles, pustules, crusted) similar to primary varicella
- May be hemorrhagic, necrotic, or confluent in immunocompromised
- Healing delayed (2-4 weeks or longer in immunocompromised vs 7-10 days in immunocompetent)

**Visceral dissemination (life-threatening):**
- VZV pneumonitis: Cough, dyspnea, tachypnea, hypoxia; CXR shows diffuse nodular/interstitial infiltrates
- Hepatitis: Elevated transaminases, jaundice
- Encephalitis: Altered mental status, seizures, ataxia, cranial nerve palsies
- Meningitis: Headache, photophobia, meningismus
- DIC: Bleeding, petechiae, abnormal coags

**High-risk populations:**
- HIV/AIDS (especially CD4 < 200)
- Hematopoietic stem cell transplant
- Solid organ transplant recipients
- Active chemotherapy
- High-dose corticosteroids (> 20 mg prednisone equivalent x > 14 days)
- Biologic immunotherapy (anti-TNF, rituximab, JAK inhibitors)

## Critical Actions

1. **Airborne + contact isolation IMMEDIATELY** — disseminated zoster is airborne transmissible (unlike dermatomal zoster, which is contact only)
2. **Acyclovir 10 mg/kg IV q8h** — start within 1 hour of suspicion
3. **Assess for visceral involvement:** CXR (pneumonitis), liver panel (hepatitis), mental status (encephalitis)
4. **IV hydration** before and during acyclovir infusion (prevent crystalline nephropathy)
5. **Ophthalmology consultation** if V1 dermatome or any ocular symptoms
6. **Notify infection control** — exposed susceptible patients/staff need post-exposure prophylaxis

## Differential Diagnosis

- Dermatomal (non-disseminated) herpes zoster — confined to 1-2 adjacent dermatomes
- Disseminated HSV — clinically indistinguishable from VZV; PCR differentiates
- Primary varicella (chickenpox) — no prior VZV history; generalized from onset
- Smallpox — synchronous deep-seated lesions (centrifugal distribution); bioterrorism concern
- Drug eruption — temporal relationship to medication, non-vesicular typically
- Contact dermatitis — follows exposure pattern, pruritic
- Eczema herpeticum — HSV superinfection of atopic dermatitis; vesicles in areas of eczema
- Impetigo — honey-crusted, superficial, positive culture for Staph/Strep

## Workup

- **VZV PCR from vesicle fluid** — gold standard; send from base of unroofed vesicle
- **VZV DFA** (direct fluorescent antibody) from lesion — rapid but less sensitive
- **VZV PCR of blood** — detects viremia; confirms dissemination
- **VZV PCR of CSF** — if CNS involvement suspected
- **CBC with differential** — lymphopenia common in immunocompromised
- **BMP** — baseline renal function for acyclovir dosing
- **Hepatic panel** — AST/ALT elevation indicates hepatic involvement
- **CXR** — diffuse nodular/interstitial infiltrates in VZV pneumonitis
- **CT chest** — more sensitive for pneumonitis (ground-glass opacities)
- **LP** if meningitis/encephalitis suspected — lymphocytic pleocytosis, elevated protein, positive VZV PCR
- **Coagulation studies** — DIC screen if disseminated
- **MRI brain** — if encephalitis features present

## Treatment

### Antiviral Therapy
- **Acyclovir 10-15 mg/kg IV q8h** (use 15 mg/kg for life-threatening disease)
- Infuse each dose over minimum 1 hour
- Maintain aggressive IV hydration (target UOP > 1 mL/kg/hr)
- **Duration:** Continue IV until:
  - No new lesions for 48 hours AND
  - Clinical improvement AND
  - Minimum 7-10 days IV
- Transition to oral valacyclovir 1000 mg PO TID to complete total 10-14 days (21 days for encephalitis)

### Renal Dosing
- CrCl 25-50 mL/min: 10 mg/kg IV q12h
- CrCl 10-25 mL/min: 10 mg/kg IV q24h
- CrCl < 10 mL/min: 5 mg/kg IV q24h; supplement post-dialysis

### Acyclovir-Resistant VZV
- **Foscarnet 40 mg/kg IV q8h** (or 60 mg/kg IV q12h)
- Aggressive hydration; monitor electrolytes (Ca, Mg, K, PO4)
- ID consultation mandatory

### Pain Management
- Gabapentin 300-1200 mg PO TID (first-line for neuropathic pain)
- Acetaminophen 1000 mg PO q6h
- NSAIDs (ibuprofen 400-600 mg PO q6h) if not contraindicated
- Opioids for severe pain (morphine 2-4 mg IV q4h PRN)
- Lidocaine 5% patch to affected dermatome (adjunctive)

### Supportive Care
- Calamine lotion or cool wet compresses for pruritus
- Non-adherent wound dressings for weeping lesions
- Bacterial superinfection: empiric antibiotics if cellulitis develops (cephalexin 500 mg PO QID or ceftriaxone 1 g IV if severe)

### Post-Exposure Prophylaxis for Contacts
- **Susceptible immunocompromised contacts (no prior VZV or vaccination):**
  - VariZIG 125 IU/10 kg IM (max 625 IU) within 10 days of exposure
  - OR Valacyclovir 1000 mg PO TID from day 3-22 post-exposure
- **Susceptible healthy contacts:** Varicella vaccine within 3-5 days of exposure
- **Pregnant contacts (susceptible):** VariZIG; consult OB

## Disposition

- **All disseminated zoster:** Admit to negative-pressure airborne isolation room
- **ICU** if: Respiratory failure (VZV pneumonitis), encephalitis, DIC, septic shock
- **Ophthalmology follow-up** if V1 involvement
- **Continue isolation until ALL lesions are crusted** — may take 10-14 days in immunocompromised
- **Notify infection control and occupational health** — staff exposure management
- **Reportable:** Varicella/disseminated zoster is reportable in most US states

## Pitfalls

1. **Treating disseminated zoster as simple dermatomal zoster.** Dermatomal zoster can be treated with oral antivirals. Disseminated zoster requires IV acyclovir and airborne isolation. The distinction is the presence of vesicles beyond the primary dermatome.

2. **Failing to isolate.** Disseminated VZV is airborne. Patients must be in negative-pressure rooms. Healthcare workers without VZV immunity must not enter the room. A single case can trigger a hospital-wide outbreak.

3. **Using oral antivirals for disseminated disease.** Oral acyclovir bioavailability is only ~20%. In disseminated or visceral VZV, only IV acyclovir achieves adequate tissue levels.

4. **Not assessing BSA and mucosal involvement systematically.** Body surface area estimation guides fluid management (similar to burn patients in extensive disease). Oral, conjunctival, and genital mucosa should all be examined.

5. **Missing visceral involvement in the absence of skin lesions.** Rarely, immunocompromised patients develop VZV hepatitis, pneumonitis, or encephalitis BEFORE or WITHOUT skin lesions. High index of suspicion + VZV PCR of blood is required.

6. **Not providing post-exposure prophylaxis to susceptible contacts.** Exposed immunocompromised and pregnant contacts need VariZIG or antiviral prophylaxis. Delays can lead to fatal primary varicella in vulnerable individuals.
